GlassScriptPhysician profile
Cherie Marie Allison
NPI 1992519177
$2,752.16
in general payments reported to CMS, 2019-2025
25 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $18.66 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.23 |
| Education | $265.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $617.69 | 2025 | Zynyz, Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $211.08 | 2025 | Datroway, Imfinzi, Calquence |
| Janssen Biotech, INC. | $167.23 | 2025 | Rybrevant, Carvykti, Talvey |
| Sobi, INC | $167.17 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $156.53 | 2025 | Lynozyfic, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $149.99 | 2025 | Breyanzi |
| Novartis Pharmaceuticals Corporation | $144.35 | 2025 | |
| Celgene Corporation | $140.58 | 2025 | Reblozyl |
| Astellas Pharma US INC | $134.00 | 2025 | Vyloy |
| Rigel Pharmaceuticals, INC. | $118.86 | 2025 | Rezlidhia |
| Genentech USA, INC. | $93.44 | 2025 | Itovebi, Venclexta, Tecentriq |
| Glaxosmithkline, LLC. | $88.55 | 2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $87.99 | 2025 | |
| Exelixis INC. | $78.65 | 2025 | Cabometyx |
| Abbvie INC. | $68.61 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $55.87 | 2025 | |
| Genmab U.S., INC. | $51.97 | 2025 | Tivdak, Epkinly |
| Array Biopharma INC | $43.90 | 2025 | Lorbrena, Braftovi, Mektovi |
| Adaptive Biotechnologies Corporation | $32.47 | 2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $31.79 | 2025 | Xpovio |
| Lilly USA, LLC | $25.74 | 2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $23.61 | 2025 | Keytruda |
| Pfizer INC. | $23.06 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.37 | 2025 | |
| Ucb, INC. | $18.66 | 2024 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherie Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.